Персона: Кабашин, Андрей Викторович
Загружается...
Email Address
Birth Date
Научные группы
Научная группа
Организационные подразделения
Организационная единица
Инженерно-физический институт биомедицины
Цель ИФИБ и стратегия развития – это подготовка высококвалифицированных кадров на базе передовых исследований и разработок новых перспективных методов и материалов в области инженерно-физической биомедицины. Занятие лидерских позиций в биомедицинских технологиях XXI века и внедрение их в образовательный процесс, что отвечает решению практикоориентированной задачи мирового уровня – диагностике и терапии на клеточном уровне социально-значимых заболеваний человека.
Статус
Руководитель научной группы "Лаборатория «Бионанофотоники"
Фамилия
Кабашин
Имя
Андрей Викторович
Имя
3 results
Результаты поиска
Теперь показываю 1 - 3 из 3
- ПубликацияОткрытый доступNuclear nanomedicine using Si nanoparticles as safe and effective carriers of 188 Re radionuclide for cancer therapy(2019) Tischenko, V. K.; Mikhailovskaya, A. A.; Popov, A. A.; Tselikov, G.; Petriev, V. M.; Deyev, S. M.; Timoshenko, V. Y.; Prasad, P. N.; Zavestovskaya, I. N.; Kabashin, A. V.; Деев, Сергей Михайлович; Тимошенко, Виктор Юрьевич; Завестовская, Ирина Николаевна; Кабашин, Андрей Викторович© 2019, The Author(s). Nuclear nanomedicine, with its targeting ability and heavily loading capacity, along with its enhanced retention to avoid rapid clearance as faced with molecular radiopharmaceuticals, provides unique opportunities to treat tumors and metastasis. Despite these promises, this field has seen limited activities, primarily because of a lack of suitable nanocarriers, which are safe, excretable and have favorable pharmacokinetics to efficiently deliver and retain radionuclides in a tumor. Here, we introduce biodegradable laser-synthesized Si nanoparticles having round shape, controllable low-dispersion size, and being free of any toxic impurities, as highly suitable carriers of therapeutic 188 Re radionuclide. The conjugation of the polyethylene glycol-coated Si nanoparticles with radioactive 188 Re takes merely 1 hour, compared to its half-life of 17 hours. When intravenously administered in a Wistar rat model, the conjugates demonstrate free circulation in the blood stream to reach all organs and target tumors, which is radically in contrast with that of the 188 Re salt that mostly accumulates in the thyroid gland. We also show that the nanoparticles ensure excellent retention of 188 Re in tumor, not possible with the salt, which enables one to maximize the therapeutic effect, as well as exhibit a complete time-delayed conjugate bioelimination. Finally, our tests on rat survival demonstrate excellent therapeutic effect (72% survival compared to 0% of the control group). Combined with a series of imaging and therapeutic functionalities based on unique intrinsic properties of Si nanoparticles, the proposed biodegradable complex promises a major advancement in nuclear nanomedicine.
- ПубликацияОткрытый доступPhase-Responsive Fourier Nanotransducers for Probing 2D Materials and Functional Interfaces(2019) Kravets, V. G.; Wu, F.; Imaizumi, S.; Grigorenko, A. N.; Kabashin, A. V.; Shipunova, V. O.; Deyev, S. M.; Кабашин, Андрей Викторович; Деев, Сергей Михайлович© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Light scattered by an object contains plethora information about the object which is distributed evenly among all possible Fourier components of light observed in the far-field. There are some cases, however, where this information is accumulated in the light confined by the object and then encoded in just a few coherent optical beams. Here, Fourier nanotransducers based on 2D plasmonic metamaterials are introduced, which are capable of confining light in 2D plane contacting with a functional interface, gathering information about its properties, and then transmitting the information into discrete optical beams with amplified phase relations. It is shown that phase of light in such beams can be used for probing dynamic physical properties of 2D materials and performing bio/chemical sensing with unprecedented sensitivity. Using a Fourier transducer based on periodic gold nanostructures, ferroelectric response from a single atomic layer of MoS 2 is resolved and studied for the first time, as well as the detection of important antibiotic chloramphenicol at fg mL −1 level is demonstrated, which several orders of magnitude better than reported in the literature. The implementation of phase-responsive Fourier nanotransducers opens new avenues in exploration of emergent 2D structures and radical improvement of biosensing technology.
- ПубликацияОткрытый доступDual Regioselective Targeting the Same Receptor in Nanoparticle-Mediated Combination Immuno/Chemotherapy for Enhanced Image-Guided Cancer Treatment(2020) Shipunova, V. O.; Komedchikova, E. N.; Kotelnikova, P. A.; Zelepukin, I. V.; Kabashin, A. V.; Prasad, P. N.; Deyev, S. M.; Кабашин, Андрей Викторович; Деев, Сергей МихайловичWhen combined with immunotherapy, image-guided targeted delivery of chemotherapeutic agents is a promising direction for combination cancer theranostics, but this approach has so far produced only limited success due to a lack of molecular targets on the cell surface and low therapeutic index of conventional chemotherapy drugs. Here, we demonstrate a synergistic strategy of combination immuno/chemotherapy in conditions of dual regioselective targeting, implying vectoring of two distinct binding sites of a single oncomarker (here, HER2) with theranostic compounds having la different mechanism of I action. We use: (i) PLGA nanoformulation, loaded with an imaging diagnostic fluorescent dye (Nile Red) and la chemotherapeutic drug (doxorubicin), and functionalized with affibody Z(HER2:342) (8 kDa); (ii) bifunctional genetically engineered DARP-LoPE (42 kDa) immunotoxin comprising of a low-immunogenic modification of therapeutic Pseudomonas exotoxin A (LOPE) and a scaffold targeting protein, DARPin9.29 (14 kDa). According to the proposed strategy, the first chemotherapeutic nanoagent is targeted by the affibody to subdomain III and 14 of HER2 with 60-fold specificity compared with nontargeted particles, while the second immunotoxin is effectively targeted by DARPin molecule to subdomain I of HER2. We demonstrate that this dual targeting strategy can enhance anticancer therapy of HER2-positive cells with a very strong synergy, which made possible 1000-fold decrease of effective drug concentration in vitro and a significant enhancement of HER2 cancer therapy compared to monotherapy in vivo. Moreover, this therapeutic combination prevented the appearance of secondary tumor nodes. Thus, the suggested synergistic strategy, utilizing dual targeting of the same oncomarker could give rise to efficient methods for aggressive tumors treatment.